Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals | Mid Cap
Health Score : 6.05Biocon Ltd shows mixed financial performance. It demonstrates strong solvency and high growth, driven by significant revenue and asset increases. The company also shows considerable financial strength in terms of capital expenditure and book value. However, liquidity is a notable weakness, indicating potential challenges in meeting short-term obligations. Efficiency is also low, suggesting difficulties in converting sales into profits and managing inventory. Profitability metrics such as ROCE, ROE and ROA are notably low. Overall, Biocon exhibits strengths in long-term growth and solvency but needs to address liquidity and efficiency to ensure sustained financial health. The inconsistency in profitability metrics suggests areas needing strategic review to improve returns.
Health Score : 6.05Biocon Ltd shows mixed financial performance. It demonstrates strong solvency and high growth, driven by significant revenue and asset increases. The company also shows considerable financial strength in terms of capital expenditure and book value. However, liquidity is a notable weakness, indicating potential challenges in meeting short-term obligations. Efficiency is also low, suggesting difficulties in converting sales into profits and managing inventory. Profitability metrics such as ROCE, ROE and ROA are notably low. Overall, Biocon exhibits strengths in long-term growth and solvency but needs to address liquidity and efficiency to ensure sustained financial health. The inconsistency in profitability metrics suggests areas needing strategic review to improve returns.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
97.92
Industry Median
19.41
Mid Cap Median
32.56
P/E RATIO
45.71
P/B RATIO
1.93
Industry Median
1.98
Mid Cap Median
1.93
P/S RATIO
N/A
Industry Median
2.06
Mid Cap Median
2.13
Others
PEG RATIO
6.38
EV/EBITDA RATIO
11.56
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹385.8 as on Jun 15, 2026.
Growth Score : 8.00Biocon demonstrates strong growth, driven by significant increases in revenue, operating profit, assets, and net income. This indicates successful strategic initiatives and market penetration. However, the negative EPS growth suggests that profitability on a per-share basis needs improvement. Sustaining this growth momentum while enhancing profitability will be key to long-term success.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 14.57 | 36.53 | 32.06 | 3.43 | 10.91 |
| Operating Profit Growth Rate | 13.41 | 34.52 | 33.33 | 1.18 | 6.18 |
| Earnings Per Share (EPS) Growth | -12.48 | -28.7 | 121.3 | -0.94 | -71.8 |
| Asset Growth Rate | 10.02 | 154.36 | 7.75 | 5 | 8.73 |
| Net Income Growth Rate | -8.75 | -16.71 | 101.87 | 10.09 | -74.18 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | BIOCON | 6.05 | 45.71 | Neutral | 3455.00 | 0.23 | 369.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
No Stock News Available at This Moment.
Biocon Ltd. is a global biopharmaceutical company focusing on biosimilars, novel biologics, and research services. Headquartered in India, it develops, manufactures, and markets biopharmaceuticals, including insulins, oncology, and immunology products, serving patients worldwide across various therapeutic areas.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Biocon Ltd's P/E ratio (TTM) is 97.92, compared to the industry median of 19.41 and large cap median of 32.56.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Biocon Ltd's P/B ratio is 1.93, compared to the industry median of 1.98 and large cap median of 1.93.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Biocon Ltd's P/S ratio is 2.70, compared to the industry median of 2.06 and large cap median of 2.13.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Biocon Ltd's PEG ratio is 6.38.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Biocon Ltd's EV/EBITDA ratio is 11.56.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Biocon Ltd's ROE is 1.08%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Biocon Ltd's ROA is 5.43%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Biocon Ltd's ROCE is 4%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Biocon Ltd's operating margin is 20.41%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Biocon Ltd's net margin is 2.18%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Biocon Ltd's current ratio is 1.01.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Biocon Ltd's debt-to-equity ratio is 0.33.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Biocon Ltd's interest coverage ratio is 1.45.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Biocon Ltd's DPS is ₹0.50.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Biocon Ltd's EPS is -71.80.
(Source line: "Ratios as of 15 Jun 2026, based on last traded price of ₹385.80. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1978
Headquarters: Bengaluru, Karnataka
Core Offerings: Biosimilars, Generic APIs, Generic Formulations, Novel Biologics, Biopharmaceutical Research Services
Stock Listing: NSE (BIOCON), BSE (532523)
Promoter: Kiran Mazumdar-Shaw / Biocon Group
Founded in 1978 by Kiran Mazumdar-Shaw as an industrial enzymes company. Biocon diversified into biopharmaceuticals in the 1990s, developing novel biologics and biosimilars. Key milestones include:
2004: Launched India's first recombinant human insulin.
2017: Became the first Indian company to launch a biosimilar (Trastuzumab) in the US.
2022: Acquired Viatris' global biosimilars business, significantly expanding Biocon Biologics' global footprint and product portfolio.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Biologics | approx 60-65% | Not Disclosed |
| Generics | approx 25-30% | Not Disclosed |
| Research Services | approx 5-10% | Not Disclosed |
Biologics: Focuses on developing, manufacturing, and commercializing biosimilars (e.g., insulins, oncology, immunology) and novel biologics for global markets, addressing chronic diseases through Biocon Biologics.
Generics: Manufactures and sells active pharmaceutical ingredients (APIs) and generic formulations across various therapeutic areas, including immunosuppressants, oncology, and specialty molecules.
Research Services: Primarily represents income from its associate company, Syngene International Ltd., which provides integrated research, development, and manufacturing services to global pharmaceutical and biotechnology companies.
Kiran Mazumdar-Shaw: Executive Chairperson. A pioneer in India's biotechnology sector, she founded Biocon and built it into a globally recognized biopharmaceutical enterprise. Siddharth Mittal: CEO & Managing Director. With over 20 years of experience in the pharmaceutical industry, he has previously served as CFO of Biocon and held leadership roles across various functions.
['Biocon Biologics Limited (majority-owned)', 'Biocon Pharma Limited', 'Biocon SA (France)', 'Biocon Sdn. Bhd. (Malaysia)']
2022: Completed the acquisition of Viatris Inc.'s global biosimilars business for approximately US$3.335 billion, a transformative deal for Biocon Biologics. This was funded through a mix of debt, equity infusion from Biocon, and strategic investors.
The Biocon Ltd share price today is ₹385.80 on NSE (BIOCON), as of 13 Sept 2026.
As of 15 Jun 2026, Biocon Ltd share price is ₹385.80, with previous close ₹385.80. Today's range is ₹385.80 to ₹385.80. The 52-week range is ₹385.80 to ₹385.80.
As of today, Biocon Ltd's market cap is ₹51,697.2 crore (Large Cap).
Biocon Ltd's current P/E ratio is 97.92, compared to the Pharmaceuticals & Biotechnology sector average of 37.50.
Biocon Ltd's current P/B ratio is 1.93.
Biocon Ltd's current dividend yield is 0.13%. Last dividend of ₹1.50 per share was declared on 10-Aug-2023.
Biocon Ltd's EPS (TTM) is ₹-71.80.
Biocon Ltd. is a global biopharmaceutical company focusing on biosimilars, novel biologics, and research services. Headquartered in India, it develops, manufactures, and markets biopharmaceuticals, including insulins, oncology, and immunology products, serving patients worldwide across various therapeutic areas.
Biocon Ltd is promoted by Kiran Mazumdar-Shaw / Biocon Group, holding 44.91% as of 15 Jun 2026.
Biocon Ltd is listed on NSE (BIOCON) and BSE (532523). Its next quarterly results are expected on Late July / Early August 2024.
Cash Earnings Per Share (Cash EPS)